Regulatory approval pathway of biosimilar products, an update
- In: D16 - Short oral communications of the FIP Social and Administrative Pharmacy Section on Thursday, 8 September 2011, 09:00-11:30
- At: Hyderabad (India) (2011)
- Type: Presentations + Posters
- By: ALJUFFALI, Ibrahim (King Saud University, Riyadh, Saudi Arabia)
Background; Several patents of therapeutic proteins and monoclonal antibodies are reaching the end of their time in different regulated regions. The end of this phase will allow similar products to share the market with the original innovator and reduce the cost on heath care systems. The aim of this study is to summarize updates on biosimilar.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019